Top

Published in:

Open Access 01-12-2021 | Diffuse Large B-Cell Lymphoma | Research article

Establishment of a typing model for diffuse large B-cell lymphoma based on B-cell receptor repertoire sequencing

Authors: Wenhua Jiang, Hailong Wang, Shiyong Zhou, Guoqing Zhu, Mingyou Gao, Kuo Zhao, Limeng Zhang, Xiaojing Xie, Ning Zhao, Caijuan Tian, Zhenzhen Zhang, Fang Yan, Yi Pan, Pengfei Liu

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

The purpose of this study was to construct a new typing model for diffuse large B-cell lymphoma (DLBCL) patients based on the B-cell receptor (BCR) and explore its potential molecular mechanism.

Methods

BCR repertoire sequencing and whole-exome sequencing were performed on formalin-fixed paraffin-embedded samples from 12 DLBCL patients. Subsequently, a typing model was built with cluster analysis, and prognostic indicators between the two groups were compared to verify the typing model. Then, mutation and bioinformatics analyses were conducted to investigate the potential biomarkers of prognostic differences between the two groups.

Results

Based on BCR sequencing data, we divided patients into two clusters (cluster 1 and cluster 2); this classification differed from the traditional typing method (GCB and non-GCB), in which cluster 1 included some non-GCB patients. The progression-free survival (PFS), overall survival (OS), metastasis and Shannon diversity index of IGH V-J and survival after chemotherapy were significantly different (P < 0.05) between the two clusters, but no statistical significance was found between the GCB and non-GCB groups. The mutation status of 248 genes was significantly different between cluster 1 and cluster 2. Among them, FTSJ3, MAGED2, and ODF3L2 were the specific mutated genes in all patients in cluster 2, and these genes could be considered critical to the different prognoses of the two clusters of DLBCL patients.

Conclusion

We constructed a new typing model of DLBCL based on BCR repertoire sequencing that can better predict the survival time after chemotherapy. FTSJ3, MAGED2, and ODF3L2 may represent key genes for the difference in prognosis between the two clusters.

Masir N, Akhter A, Roshan TM, Florence CS, Abdul-Rahman F, Tumian NR, Kean-Chang P, Elyamany G, Shabani-Rad MT, Mansoor A. Diffuse large B-cell lymphoma in southeast Asian cohort: expression patterns of B-cell receptor (BCR) repertoire and its linkage with molecular subtypes and response to R-CHOP therapy. J Clin Pathol. 2019;72(9):630–5. https://doi.org/10.1136/jclinpath-2019-205837.CrossRefPubMed

Xu W, Liang JH. Advances in novel genotyping and molecular targeting therapy for diffuse large B cell lymphoma. J Clin Hematol. 2020;33(9):594–8.

Blansky D, Mantzaris I, Rohan T, Hosgood HD. The influence of rurality, race and ethnicity on non-Hodgkin lymphoma incidence. Cl Lymph Myelom Leuk. 2020;20(10):668–76. https://doi.org/10.1016/j.clml.2020.05.010.CrossRef

Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922–6. https://doi.org/10.1038/nm.3884.CrossRefPubMed

Ghraichy M, Galson JD, Kelly DF, Trück J. B-cell receptor repertoire sequencing in patients with primary immunodeficiency: a review. Immunology. 2018;153(2):145–60. https://doi.org/10.1111/imm.12865.CrossRefPubMed

Gadala-Maria D, Gidoni M, Marquez S, Vander Heiden JA, Kos JT, Watson CT, O'Connor KC, Yaari G, Kleinstein SH. Identification of subject-specific immunoglobulin alleles from expressed repertoire sequencing data. Front Immunol. 2019;10:129. https://doi.org/10.3389/fimmu.2019.00129.CrossRefPubMedPubMedCentral

Zhang W, Du Y, Su Z, Wang CX, Zeng XJ, Zhang RF, et al. IMonitor: a robust pipeline for TCR and BCR repertoire analysis. Genetics. 2015;201(2):459–72. https://doi.org/10.1534/genetics.115.176735.CrossRefPubMedPubMedCentral

Petrova VN, Muir L, McKay PF, Vassiliou GS, Smith KG, Lyons PA, et al. Combined influence of B-cell receptor rearrangement and somatic hypermutation on B-cell class-switch fate in health and in chronic lymphocytic leukemia. Front Immunol. 2018;9:1784. https://doi.org/10.3389/fimmu.2018.01784.CrossRefPubMedPubMedCentral

Tanaka S, Baba Y. B Cell Receptor Signaling. In: Wang JY, editor. B Cells in Immunity and Tolerance. Advances in Experimental Medicine and Biology. Springer, Singapore, vol. 1254; 2020. p. 23–36.CrossRef

10.

Setliff I, Shiakolas AR, Pilewski KA, Murji AA, Mapengo RE, Janowska K, Richardson S, Oosthuysen C, Raju N, Ronsard L, Kanekiyo M, Qin JS, Kramer KJ, Greenplate AR, McDonnell WJ, Graham BS, Connors M, Lingwood D, Acharya P, Morris L, Georgiev IS. High-throughput mapping of B cell receptor sequences to antigen specificity. Cell. 2019;179(7):1636–46. https://doi.org/10.1016/j.cell.2019.11.003.CrossRefPubMedPubMedCentral

11.

Zhang F, Gan R, Zhen Z, Hu X, Li X, Zhou F, et al. Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals. Sig Transduct Target Ther. 2020;5(156):1–11.

12.

Khan TA, Friedensohn S, de vries Gorter AR, Straszewski J, Ruscheweyh H, Reddy ST. Accurate and predictive antibody repertoire profiling by molecular amplification fingerprinting. Sci Adv. 2016;2(3):e1501371.CrossRef

13.

Li JT, Zhang QY. Targeted therapy and immunotherapy in diffuse large B-cell lymphoma. Medical Recapitulate. 2019;25(12):2372–6.

14.

Shalapour S, Font-Burgada J, Di Caro G, Zhong ZY, Sanchez-Lopez E, Dhar D, et al. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature. 2015;521(7550):94–8. https://doi.org/10.1038/nature14395.CrossRefPubMedPubMedCentral

15.

Ayadi L, Galvanin A, Pichot F, Marchand V, Motorin Y. RNA ribose methylation (2′-O-methylation): occurrence, biosynthesis and biological functions. Biochim Biophys Acta Gene Regul Mech. 2019;1862(3):253–69. https://doi.org/10.1016/j.bbagrm.2018.11.009.CrossRefPubMed

16.

Ringeard M, Marchand V, Decroly E, Motorin Y, Bennasser Y. FTSJ3 is an RNA 2′-O-methyltransferase recruited by HIV to avoid innate immune sensing. Nature. 2019;565(7740):500–4. https://doi.org/10.1038/s41586-018-0841-4.CrossRefPubMed

17.

Manning M, Jiang Y, Wang R, Liu LX, Rode S, Bonahoom M, Kim S, Yang ZQ. Pan-cancer analysis of RNA methyltransferases identifies FTSJ3 as a potential regulator of breast cancer progression. RNA Biol. 2020;17(4):474–86. https://doi.org/10.1080/15476286.2019.1708549.CrossRefPubMedPubMedCentral

18.

Kirkin AF, Dzhandzhugazyan KN, Zeuthen J. Cancer/testis antigens: structural and immunobiological properties. Cancer Investig. 2002;20(2):222–36. https://doi.org/10.1081/CNV-120001150.CrossRef

19.

Papageorgio C, Brachmann R, Zeng J, Culverhouse R, Zhang WH, Mcleod H. MAGED2: a novel p53-dissociator. Int J Oncol. 2007;31(5):1205–11.PubMed

20.

Barker PA, Salehi A. The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J Neurosci Res. 2002;67(6):705–12. https://doi.org/10.1002/jnr.10160.CrossRefPubMed

Title: Establishment of a typing model for diffuse large B-cell lymphoma based on B-cell receptor repertoire sequencing
Authors: Wenhua Jiang
Hailong Wang
Shiyong Zhou
Guoqing Zhu
Mingyou Gao
Kuo Zhao
Limeng Zhang
Xiaojing Xie
Ning Zhao
Caijuan Tian
Zhenzhen Zhang
Fang Yan
Yi Pan
Pengfei Liu
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Cytostatic Therapy
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08015-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Viral hepatitis associated hepatocellular carcinoma on the African continent, the past, present, and future: a systematic review

Kaempferol induces ROS-dependent apoptosis in pancreatic cancer cells via TGM2-mediated Akt/mTOR signaling

Multidisciplinary tumor boards and their analyses: the yin and yang of outcome measures

Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma

Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer